Evidence map›Paper›PMID 30071629›Full record

ArticleGenes2018

Analysis of Candidate Idarubicin Drug Resistance Genes in MOLT-3 Cells Using Exome Nuclear DNA.

Tomoyoshi Komiyama, Atsushi Ogura, Takehito Kajiwara, Yoshinori Okada, Hiroyuki Kobayashi

Open access · goldAbstract read
In one paragraph

Article in Genes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tomoyoshi KomiyamaDepartment of Clinical Pharmacology, Tokai University School of Medicine, Kanagawa 259-1193, Japan. komiyama@tokai-u.jp.ORCID 0000-0003-2138-0084
Atsushi OguraNagahama Institute of Bio-Science and Technology, Shiga 526-0829, Japan. a_ogura@nagahama-I-bio.ac.jp.ORCID 0000-0002-5610-9940
Takehito KajiwaraNagahama Institute of Bio-Science and Technology, Shiga 526-0829, Japan. b312009@m.nagahama-I-bio.ac.jp.ORCID 0000-0002-5610-9940
Yoshinori OkadaSupport Center for Medical Research and Education, Tokai University, Kanagawa 259-1193, Japan. yosi@is.icc.u-tokai.ac.jp.
Hiroyuki KobayashiDepartment of Clinical Pharmacology, Tokai University School of Medicine, Kanagawa 259-1193, Japan. hkobayas@is.icc.u-tokai.ac.jp.
Tokai University · JPNagahama Institute of Bio-Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various gene alterations related to acute leukemia are reported to be involved in drug resistance. We investigated idarubicin (IDR) resistance using exome nuclear DNA analyses of the human acute leukemia cell line MOLT-3 and the derived IDR-resistant cell line MOLT-3/IDR. We detected mutations in MOLT-3/IDR and MOLT-3 using both Genome Analysis Toolkit (GATK) and SnpEff program. We found 8839 genes with specific mutations in MOLT-3/IDR and 1162 genes with accompanying amino acid mutations. The 1162 genes were identified by exome analysis of polymerase-related genes using Kyoto Encyclopedia of Genes and Genomes (KEGG) and, among these, we identified genes with amino acid changes. In resistant strains,

Indexed as

drug resistancegene polymorphismgenetic variationsidarubicinleukemiaMOLT-3

Identifiers

PMID30071629
PMCPMC6116115
OpenAlexW2803285413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.